The approach also seemed to work regardless of whether the tumour was PD-L1 positive or negative ... to produce a robust and long-lasting CD8 killer T cell response against cancer cells," he ...

CD8 + T cells that normally kill cancer cells ... three markers involved with antigen presentation, MHCI, MHCII, and PD-L1, and their release of two markers of immunogenic cell death, ATP and ...

While CTLA-4, PD-1, and PD-L1 are the primary focus of current ICIs, there are several other immune regulatory molecules that scientists are investigating as potential future targets for ICI therapies ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

Additionally, PLT012 reshapes the exhaustion profile of cytotoxic CD8+ T cells by expanding both ... immune checkpoint inhibitors such as PD-1 or PD-L1 inhibitors. Other than oncology, the unique ...